Adverse events(during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
Adverse events (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people undergoing bariatric surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Adverse events · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
1 finding from 1 review
Adverse events · spatial neglect or inattention following stroke and other adult‐acquired non‐progressive brain injury
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · spatial neglect or inattention following stroke and other adult‐acquired non‐progressive brain injury
1 finding from 1 review
Adverse events · spatial neglect or inattention following stroke and other adult‐acquired non‐progressive brain injury
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · spatial neglect or inattention following stroke and other adult‐acquired non‐progressive brain injury
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review